Chris, yes, the bridge data will be focusing mostl
Post# of 30028
Posted On: 09/03/2014 11:38:28 AM
Chris, yes, the bridge data will be focusing mostly on univariant biomarkers. This is why our mb discussion regarding LymPro needs to evolve. In my post about this yesterday I went into detail about CD 69 and the six univariant sub-classes of white blood cells that demonstrate the presence of CD 69 in the blood, indicating alzheimers.
I think we need to actually get into this science a bit more than we have in order to appreciate the bridge test results!
One of the highlights I got from Gerald's in depth discussion of LymPro was that CD 19, our most accurate univariant tag, is about 80% accurate. Gerald says that the Big AD Pharma that they've talked to love that result! It may not be much more accurate than the screening tests they're currently using, but it is much CHEAPER & EASIER!!! They can use it as a companion diagnostic test to screen the larger set of potential patients they are considering testing, and the cheaper LmPro can boil down that larger set to a smaller set, more likely to have AD. Then they can use their more expensive screening test on that smaller group, and they save tons of money by using these 2 tests in tandem, and they're likely to have a purer pool of AD patients to work on, which is the goal.
LymPro is PRACTICAL!!! The Georgetown blood test has more univariants than LymPro, but they are all in the 50% accuracy range by themselves. Whereas, CD 19 is 80% by itself! And it is cheap. And it is ready by December, whereas Georgetown's won't be ready for 2 to 4 years!
People need to understand the guts of LymPro to appreciate where we are and it's massive potential. I doubt very many AMBS shareholders have bothered to get into the CD stuff. If you haven't, you probably tuned Gerald out when he spent 10 minutes yesterday talking about it. And you would have missed the best part of the CC.
We've got to upgrade our discussion about LymPro BEFORE the Bridge Test data is released!!
I think we need to actually get into this science a bit more than we have in order to appreciate the bridge test results!
One of the highlights I got from Gerald's in depth discussion of LymPro was that CD 19, our most accurate univariant tag, is about 80% accurate. Gerald says that the Big AD Pharma that they've talked to love that result! It may not be much more accurate than the screening tests they're currently using, but it is much CHEAPER & EASIER!!! They can use it as a companion diagnostic test to screen the larger set of potential patients they are considering testing, and the cheaper LmPro can boil down that larger set to a smaller set, more likely to have AD. Then they can use their more expensive screening test on that smaller group, and they save tons of money by using these 2 tests in tandem, and they're likely to have a purer pool of AD patients to work on, which is the goal.
LymPro is PRACTICAL!!! The Georgetown blood test has more univariants than LymPro, but they are all in the 50% accuracy range by themselves. Whereas, CD 19 is 80% by itself! And it is cheap. And it is ready by December, whereas Georgetown's won't be ready for 2 to 4 years!
People need to understand the guts of LymPro to appreciate where we are and it's massive potential. I doubt very many AMBS shareholders have bothered to get into the CD stuff. If you haven't, you probably tuned Gerald out when he spent 10 minutes yesterday talking about it. And you would have missed the best part of the CC.
We've got to upgrade our discussion about LymPro BEFORE the Bridge Test data is released!!
(0)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼